Follow Us:Respiratio 2023; 13, (1-2): 95-101
SKRINING KARCINOMA PLUĆA U AP VOJVODINI
LUNG CANCER SCREENING IN VOJVODINA PROVINCE
Jelena Đekić Malbaša1,2,Darijo Bokan1, Bojan Zarić1,2, Tomi Kovačević1,2, Goran Stojanović1,3, Dragan Dragišić1, Ivan Kuhajda1,2
1Institut za plućne bolesti Vojvodine, Sremska Kamenica, Srbija
2Medicinski fakultet Novi Sad, Univerzitet u Novom Sadu, Srbija
3Farmaceutski fakultet Novi Sad, Univerzitet Privredna akademija Novi Sad, Srbija
Original Research
Naučni članak
Uvod: Bolje preživljavanje obolelih od karcinomom pluća moguće je postavljanjem dijagnoze u ranom stadijumu bolesti. Primena niskodoznog CT u populaciji visokog rizika za nastanak karcinoma pluća omogućava detekciju karcinoma u ranijim stadijumima bolesti i doprinosi poboljšanom preživljavanju obolelih.
Metod: Retrospektivna analiza rezultata i ishoda skrininga karcinoma pluća primenom niskodoznog CT sprovedena u Institutu za plućne bolesti Vojvodine (IPBV) u periodu od 20.09.2020. do 31.12.2022. godine. U skrining su uključene osobe uzrasta 50-74 godine, bivši pušači (preslali da puše pre ≤ 10 godina) i aktvni pušači, sa ≥30 paklica-godina, ili ≥20 paklica-godina sa prisutnim dodatnim faktorima rizika.
Rezultati: U posmatranom periodu je izvršeno ukupno 3432 snimanja primenom LDCT, od čega je 62,3% (2138) prvih pregleda. Sumnjiv i veoma sumnjiv nalaz (Lung RADS 4) je zabeležen kod 196 (9, 2%) ispitanika. Nalaz emfizema nakon LDCT je registrovan kod 709 (33, 2%) ispitanika. Procenat detekcije karcinoma pluća je iznosio 1,8% (40/2138). Od ukupnog broja potvrđenih karcinoma pluća, 88,5% (23/26) je otkriveno nakon inicijalnog LDCT, dok je preostalih 11,5% (3/26) potvrđeno nakon perioda praćenja. 75% (30/40) dokazanih karcinoma pluća je bilo u stadijumima I do IIIA.
Nesitnoćelijski karcinomi (adenokarcinom 60,0% (24/40), skvamozni 22,5% (9/40) i drugi nesitnoćelijski 5,0% (2/40)) činili su 85,7% (35/40), dok su sitnoćelijski potvrđeni u 12,5% (5/40).
Zaključak: Karcinomi pluća u skrining programu su najčešće detektovani u ranom stadijumu bolesti. Skriningom karcinoma pluća potrebno je obuhvatiti populaciji visokog rizika na teritoriji cele Republike.
Ključne reči: skrining karcinoma pluća, niskodozni CT, rani stadijum bolesti
LITERATURA
|
1. Mikljuš D, Živković Perišić S, Božić Z. Malignant tumors in Republic of Serbia 2019. Belgrade: Institute of Public Health of Serbia; 2021. (https://www.batut.org.rs/download/publikacije/maligniTumoriURepubliciSrbiji2019.pdf). |
|
|
|
|
|
2. Lung cancer in Serbia. Cavic M, Kovacevic T, Zaric B, Stojiljkovic D, Korda NJ, Rancic M, Jankovic R, Radosavljevic D, Stojanovic G, Spasic J. Lung Cancer in Serbia. J Thorac Oncol. 2022 Jul;17(7):867-872. [CrossRef] PMid:35750454 |
|
|
|
|
|
3. Lung cancer. Lancet 2021. Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021 Aug 7;398(10299):535-554. [CrossRef] |
|
|
|
|
|
4. Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A. Epidemiology of lung cancer. Contemp Oncol (Pozn). 2021;25(1):45-52. doi:10.5114/wo.2021.103829. |
|
|
|
|
|
5. https://www.wcrf.org/cancer-trends/lung-cancer-statistics/ |
|
|
|
|
|
6. Eric W. Zhang, Jo-Anne O. Shepard, Anderson Kuo, Wariya Chintanapakdee, Florence Keane, Justin F. Gainor, Mari Mino-Kenudson, Michael Lanuti, Inga T. Lennes, Subba R. Digumarthy; Characteristics and Outcomes of Lung Cancers Detected on Low-Dose Lung Cancer Screening CT. Cancer Epidemiol Biomarkers Prev 1 August 2021; 30 (8): 1472-1479. |
|
|
|
|
|
7. van der Aalst CM, Ten Haaf K, de Koning HJ. Implementation of lung cancer screening: what are the main issues? Transl Lung Cancer Res. 2021 Feb;10(2):1050-1063. |
|
|
|
|
|
8. National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409. [CrossRef] PMid:21714641 PMCid:PMC4356534 |
|
|
|
|
|
9. de Koning HJ, van der Aalst CM, ten Haaf K, et al. PL02.05 - Effects of Volume CT Lung Cancer Screening: Mortality Results of the NELSON Randomised-Controlled Population Based Trial. Toronto, Canada: 19th World Conference on Lung Cancer, 2018. |
|
|
|
|
|
10. Sadate A, Occean BV, Beregi JP, et al. Systematic review and meta-analysis on the impact of lung cancer screening by low-dose computed tomography. Eur J Cancer 2020;134:107-14. [CrossRef] PMid:32502939 |
|
|
|
|
|
11. Lung-RADS score American College of Radiology. Lung CT Screening Reporting and Data System (Lung-RADS). Available from: http://www.acr.org/Quality-Safety/Resources/LungRADS. |
|
|
|
|
|
12. Law on Personal Data Protection ("Official Gazette of RS" No.87/2018-54) |
|
|
|
|
|
13. Zhang EW, Shepard JO, Kuo A, Chintanapakdee W, Keane F, Gainor JF, Mino-Kenudson M, Lanuti M, Lennes IT, Digumarthy SR. Characteristics and Outcomes of Lung Cancers Detected on Low-Dose Lung Cancer Screening CT. Cancer Epidemiol Biomarkers Prev. 2021 Aug;30(8):1472-1479. [CrossRef] PMid:34108138 |
|
|
|
|
|
14. de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, et al Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med 2020;382:503-13. [CrossRef] PMid:31995683 |
|
|
|
|
|
15. Pastorino U, Silva M, Sestini S, Sabia F, Boeri M, Cantarutti A, et al Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy. Ann Oncol 2019;30:1162-9. [CrossRef] PMid:30937431 PMCid:PMC6637372 |
|
|
|
|
|
16. Meza R, Jeon J, Toumazis I, ten Haaf K, Cao P, Bastani M, et alEvaluation of the benefits and harms of lung cancer screening with low-dose computed tomography: a collaborative modeling study for the U.S. Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality; 2021. [CrossRef] PMid:33687469 PMCid:PMC9208912 |
|
|
|
|
|
17. Pinsky PF, Gierada DS, Black W, Munden R, Nath H, Aberle D, et all. Performance of Lung-RADS in the National Lung Screening Trial: a retrospective assessment. Ann Intern Med. 2015 Apr 7;162(7):485-91. [CrossRef] PMid:25664444 PMCid:PMC4705835 |
|
|
|
|
|
18. van der Aalst CM, Ten Haaf K, de Koning HJ. Implementation of lung cancer screening: what are the main issues? Transl Lung Cancer Res. 2021 Feb;10(2):1050-1063. |
|
|
|
|
|
19. Ten Haaf K, van Rosmalen J, de Koning HJ. Lung cancer detectability by test, histology, stage, and gender: estimates from the NLST and the PLCO trials. Cancer Epidemiol Biomarkers Prev 2015;24:154-61.[CrossRef] PMid:25312998 PMCid:PMC4357842 |
|
|
|
|
|
20. Handy JR Jr, Skokan M, Rauch E, Zinck S, Sanborn RE, Kotova S, Wang M. Results of Lung Cancer Screening in the Community. Ann Fam Med. 2020 May;18(3):243-249. |
|
|
|
|
|
21. Bokan D. Impact of demographic factors and tumor characteristics on the lung cancer patients survival in Vojvodina. Dissertation. Faculty of medicine Novi Sad: University of Novi Sad, 2020. |
|
|
|
|
|
22. Tanner NT, Kanodra NM, Gebregziabher M, et al. The Association between Smoking Abstinence and Mortality in the National Lung Screening Trial. Am J Respir Crit Care Med 2016;193:534-41. [CrossRef] PMid:26502000 |
|
Jelena Đekić Malbaša
Put doktora Goldmana 4
21204 Sremska Kamenica
+38160971039
djekicjela@yahoo.com